Market Overview

PTC Therapeutics Q4 Earnings Preview


PTC Therapeutics (NASDAQ: PTCT) announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

PTC Therapeutics' per-share loss will be near 14 cents per share on sales of $74.4 million, according to Wall Street analysts.

PTC Therapeutics' loss in the same period a year ago was 78 cents per share. Quarterly sales came in at $25.19 million. If the company were to post earnings inline with the consensus estimate when it reports Tuesday, EPS would be up 82.05 percent. Revenue would be up 195.34 percent from the year-ago period.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.47 -1.3 -1.03 -1.08
EPS Actual -0.82 -0.44 -0.85 -0.78

Stock Performance

For a full 12 months, the return has risen by 143.19 percent. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The popular rating by analysts on PTC Therapeutics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

PTC Therapeutics is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here.


Related Articles (PTCT)

View Comments and Join the Discussion!

Posted-In: Earnings News Previews Trading Ideas